Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1530/eje.0.1510107
European Journal of Endocrinology, Vol 151, Issue 1, 107-112
Copyright © 2004 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Welin, S.
Right arrow Articles by Eriksson, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Welin, S.
Right arrow Articles by Eriksson, B.
Clinical Studies

High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours

SV Welin, ET Janson, A Sundin, M Stridsberg, E Lavenius, D Granberg, B Skogseid, KE Oberg, and BK Eriksson

Department of Medical Sciences, University Hospital, Uppsala, Sweden.

OBJECTIVE: High-dose somatostatin analogue treatment has shown an antiproliferative effect in one study including patients with neuroendocrine tumours. To explore this therapeutic strategy further, we have studied the effect of a high-dose formula of octreotide, octreotide pamoate, in midgut carcinoid patients. DESIGN AND METHODS: Twelve patients with advanced midgut carcinoid tumours with a median duration of disease of more than 5 years were included. All were in a progressive state despite several previous treatment modalities. Octreotide pamoate (160 mg) was given as an intramuscular injection every 2 weeks for 2 months and then monthly. Radiological and biochemical responses were monitored. RESULTS: Tumour size and biochemical markers were stabilised for a median of 12 months in 75% of the patients. Ten patients had symptomatic improvement of flush and diarrhoea. CONCLUSION: In this group of patients with advanced midgut carcinoid tumours and progressive disease, octreotide pamoate managed to improve symptoms, and stabilise hormone production and tumour growth in 75% of the patients. We believe that high-dose treatment with somatostatin analogues can be an important addition to the therapeutic arsenal for patients with advanced progressive midgut carcinoid tumours.


This article has been cited by other articles:


Home page
 Cleveland Clinic Journal of MedicineHome page
G. AGARWAL, K. OBIDEEN, and M. WEHBI
Carcinoid tumors: What should increase our suspicion?
Cleveland Clinic Journal of Medicine, December 1, 2008; 75(12): 849 - 855.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
P. R. Bhosale, M. Patnana, C. Viswanathan, and J. Szklaruk
The Inguinal Canal: Anatomy and Imaging Features of Common and Uncommon Masses
RadioGraphics, May 1, 2008; 28(3): 819 - 835.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
A. F. Scarsbrook, A. Ganeshan, J. Statham, R. V. Thakker, A. Weaver, D. Talbot, P. Boardman, K. M. Bradley, F. V. Gleeson, and R. R. Phillips
Anatomic and Functional Imaging of Metastatic Carcinoid Tumors
RadioGraphics, March 1, 2007; 27(2): 455 - 477.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N Fazio, F de Braud, G Delle Fave, and K Oberg
Interferon-{alpha} and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination?
Ann. Onc., January 1, 2007; 18(1): 13 - 19.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 European Society of Endocrinology.